Compare HCA Health Inc (HCA) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HCA Health Inc vs JPMorgan Chase & Co — how do they compare? HCA Health Inc trades at $445.89 (market cap $96.35B), while JPMorgan Chase & Co trades at $331.24 (market cap $880.98B). The key difference: JPMorgan Chase & Co is far larger — about 9.1× HCA Health Inc's market cap, and JPMorgan Chase & Co pays the higher dividend (1.99%). Which is the better fit depends on your goals — on Pluang, investors hold HCA Health Inc for 76 Days and JPMorgan Chase & Co for 127 Days on average.
| HCA | JPM | |
|---|---|---|
Market Cap | $96.35B | $880.98B |
Volume | 1,079,453 | 7,721,661 |
Sector | Health | Financials |
52-Week High | $545.13 | $365.18 |
52-Week Low | $361.32 | $282.84 |
Typical Hold Time | 76 Days | 127 Days |
Enterprise Value | $146.88B | $1.82T |
Dividend Yield | 0.7% | 1.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare (HCA) trades at $439.17, up 1.61% today, with a bullish technical signal and strong fundamental performance. Revenue grew to $75.6 billion in 2025, with net income reaching $6.78 billion, and the company has beaten EPS estimates for three consecutive quarters. Recent news includes an upcoming Q3 2026 earnings call and the completion of the College of Health Care Professions acquisition, highlighting operational expansion.
The outlook remains positive with a consensus price target of $461.12, though risks include ongoing legal investigations and high debt levels. Earnings growth and cost controls support upside potential, but investors should monitor regulatory developments and payer-mix pressures that could impact margins.
JPMorgan Chase (JPM) trades at $329.58, down 0.51% with a bearish technical signal. The stock shows strong fundamentals with revenue growth from $181.85B in 2025 to $194.9B projected for 2026, and a net income margin of 33.38%. Recent earnings beat expectations in Q1 and Q2 2026, while analyst consensus remains positive with a $373.18 price target. However, negative cash flow trends and geopolitical risks noted by CEO Jamie Dimon present headwinds.
Outlook: JPM offers solid value with a P/E of 14.2 and high ROE of 18.43%, supported by earnings beats and institutional buying. Risks include sustained negative operating cash flow, rising debt-to-asset ratio (11.34% in 2024), and macroeconomic volatility. The stock is a hold for long-term investors, with upside to consensus target if earnings momentum continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
